Freenome’s SPAC merger agreement comes as the liquid biopsy developer prepares for potential 2026 commercialization of SimpleScreen, a colorectal cancer test currently under FDA review.

Guardant Health is touting the results of a new study showing its Reveal blood test can detect whether chemotherapy is failing months before evidence shows up on regular scans, allowing oncologists to ...

The cancer-focused biotech surprised on the upside for both revenue and profitability in its latest reported quarter. Revenue rose by almost 40% year over year in that period. In its third quarter, ...

Guardant's oncology and screening businesses are expanding at a rapid pace. New partnerships should drive further gains. 10 stocks we like better than Guardant Health › Shares of Guardant Health ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Guardant Health, Inc. is one of them. Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, ...

What if you could get checked for colon cancer with only a routine blood draw? A new blood test in Michigan is making the process much easier. No bowel prep, no sedation and no awkward stool kit to ...

Streamlined access to Guardant Shield ™ will help millions of people residing in senior living facilities to stay up to date on colorectal cancer screening LabFlorida/SunDX will provide patients in ...

Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62% Performance of the Shield algorithm was validated in expanded ...